Skip to main content

Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF).

Publication ,  Journal Article
Ezekowitz, JA; Podder, M; Hernandez, AF; Armstrong, PW; Starling, RC; O'Connor, CM; Califf, RM
Published in: BMJ Open
March 17, 2016

OBJECTIVES: Limited data exist assessing the relationship between ambulance versus self-presentation and outcomes in patients with acute heart failure (AHF). SETTING: Clinical trial sites in North America. PARTICIPANTS: 1068 patients enrolled in the Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial. PRIMARY AND SECONDARY OUTCOME MEASURES: The association between ambulance use and dyspnoea improvement, 30-day mortality or HF rehospitalisation and 180-day mortality. RESULTS: Of the 1068 patients in the substudy, 832 (78%) self-presented (SP) and 236 (22%) patients presented via ambulance. Patients presenting via ambulance were older, more likely to be female, have a higher ejection fraction but similar natriuretic peptide levels as patients who SP. Patients presenting by ambulance (compared with SP) trended towards more dyspnoea improvement at 6 (p=0.09) and 24 h (p=0.10). The co-primary end point (30-day mortality or HF rehospitalisation) was similar between groups (ambulance 12.2% vs SP 11.4%, p=0.74). Patients who presented by ambulance had a higher 30-day and 180-day mortality rate than those who SP (30-day: 4.3% vs 2.2%, p=0.08; 180-day: 15.1% vs 10.3%, p=0.04). After adjustment for baseline characteristics, patients arriving by ambulance (compared with SP) had a 2-fold high risk of 30-day mortality (OR 2.12, 95% CI 0.94 to 4.79), but no relationship to the composite of 30-day mortality/HF rehospitalisation (OR 1.01, 95% CI 0.63 to 1.63). CONCLUSIONS: Among patients with AHF, 30-day and 180-day mortality is 1.5-2 times higher for those with presenting via ambulance compared with patients who self-present. Understanding patient-related and system-related factors of ambulance use for patients with AHF is important. TRIAL REGISTRATION NUMBER: NCT00475852.

Duke Scholars

Published In

BMJ Open

DOI

EISSN

2044-6055

Publication Date

March 17, 2016

Volume

6

Issue

3

Start / End Page

e010201

Location

England

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Risk Factors
  • Randomized Controlled Trials as Topic
  • Prospective Studies
  • Patient Readmission
  • North America
  • Natriuretic Peptide, Brain
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ezekowitz, J. A., Podder, M., Hernandez, A. F., Armstrong, P. W., Starling, R. C., O’Connor, C. M., & Califf, R. M. (2016). Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF). BMJ Open, 6(3), e010201. https://doi.org/10.1136/bmjopen-2015-010201
Ezekowitz, Justin A., Mohua Podder, Adrian F. Hernandez, Paul W. Armstrong, Randall C. Starling, Christopher M. O’Connor, and Robert M. Califf. “Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF).BMJ Open 6, no. 3 (March 17, 2016): e010201. https://doi.org/10.1136/bmjopen-2015-010201.
Ezekowitz JA, Podder M, Hernandez AF, Armstrong PW, Starling RC, O’Connor CM, et al. Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF). BMJ Open. 2016 Mar 17;6(3):e010201.
Ezekowitz, Justin A., et al. “Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF).BMJ Open, vol. 6, no. 3, Mar. 2016, p. e010201. Pubmed, doi:10.1136/bmjopen-2015-010201.
Ezekowitz JA, Podder M, Hernandez AF, Armstrong PW, Starling RC, O’Connor CM, Califf RM. Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF). BMJ Open. 2016 Mar 17;6(3):e010201.

Published In

BMJ Open

DOI

EISSN

2044-6055

Publication Date

March 17, 2016

Volume

6

Issue

3

Start / End Page

e010201

Location

England

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Risk Factors
  • Randomized Controlled Trials as Topic
  • Prospective Studies
  • Patient Readmission
  • North America
  • Natriuretic Peptide, Brain
  • Middle Aged
  • Male